2024-514879-17-00
Not yet recruiting
Phase 3
Randomised Phase III Trial of First Line Intraperitoneal Paclitaxel and Systemic Therapy versus Systemic Therapy Alone in Gastric Cancer Patients with Peritoneal Metastases
Karolinska University Hospital8 sites in 4 countries96 target enrollmentStarted: August 4, 2025Last updated:
Overview
- Phase
- Phase 3
- Status
- Not yet recruiting
- Sponsor
- Karolinska University Hospital
- Enrollment
- 96
- Locations
- 8
- Primary Endpoint
- Overall survival (OS), defined as time from randomisation to death from any cause.
Overview
Brief Summary
To compare overall survival (OS) for patients randomised to intraperitoneal (IP) paclitaxel and standard systemic therapy (ST) versus those randomised to standard ST only.
Eligibility Criteria
- Ages
- 18 years to 65+ years (18-64 Years, 65+ Years)
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Gastric or gastro-oesophageal junction Siewert type II or III adenocarcinoma verified by biopsy or cytology from the primary tumour
- •Life expectancy of at least three months.
- •Male participants are eligible to participate if they agree to the following requirements during the intervention period and for at least 6 months after the last dose of study intervention, which corresponds to the time needed to eliminate reproductive safety risk of the study intervention(s) plus an additional 90 days (a spermatogenesis cycle): o Refrain from donating sperm. PLUS either: • Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent. OR • Must agree to use contraception/barrier as detailed below. • Agree to use a male condom when engaging in any activity that allows for passage of ejaculate to another person. • Use of an additional highly effective contraceptive method with a failure rate of <1% per year for a female partner of childbearing potential.
- •A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least 1 of the following conditions applies: • Is not a WOCBP. OR • Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of <1% per year), preferably with low user dependency during the intervention period and for at least 9 months after the last dose of study intervention, which corresponds to the time needed to eliminate any reproductive safety risk of the study intervention(s). As for participants using a highly effective method that is user dependent, this contraception method must be used together with a second effective method of contraception. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention.
- •Peritoneal metastasis verified by biopsy, or cytology from ascites or peritoneal wash fluid
- •Staging laparoscopy with assessment of peritoneal cancer index (PCI) performed less than four weeks before enrolment.
- •Patients with tumour positive cytology (CYT+) without clinically manifest peritoneal metastases at baseline (PCI 0) staging laparoscopy can be included if they persist to be CYT+ after at least four cycles of systemic chemotherapy.
- •Adequate bone marrow function (neutrophil count >1500/mm3, hemoglobin >8.0 g/dl and platelet count >100 000/mm3).
- •Adequate liver function (bilirubin within 1.5x of the upper limit of normal, AST/ALT within 3x of upper limit of normal).
- •Adequate renal function (serum creatinine within1.5x of the upper limit of normal or Glomerular Filtration Rate via Cockcroft-Gault Formula>50mL.
Exclusion Criteria
- •Comorbidity that does not allow treatment with ST or IP paclitaxel.
- •Ongoing or recent participation (within 30 days) in a clinical trial with an investigational medicinal product.
- •Confirmed or suspected severe abdominal adhesions, for example after previous abdominal surgery, which do not allow effective IP paclitaxel treatment.
- •Distant metastases (including M1 lymph node mestastases according to AJCC 8th edition TNM classification) other than peritoneal, with the specific exception of ovarian, which are permitted.
- •Symptomatic ascites already requiring drainage for palliation, or expected to require drainage in the short term, i.e within the next three weeks (radiological ascites without significant symptoms is acceptable).
- •Gastric cancer peritoneal reccurence which is diagnosed within 6 months after curative intent surgery (patients with recurrence diagnosed 6 months or more after curative intent surgery may be included).
- •Severe coagulation disorder which precludes surgical interventions such as staging laparoscopies and SIPC placement
- •Previously received more than 2 cycles of palliative-intent systemic chemotherapy (with the specific exception of cytology positive patients without manifest peritoneal metastases) for the current cancer disease.
- •Another malignancy that can affect survival within the next three years.
- •Known or suspected allergies against any product included in the trial interventions.
Outcomes
Primary Outcomes
Overall survival (OS), defined as time from randomisation to death from any cause.
Overall survival (OS), defined as time from randomisation to death from any cause.
Secondary Outcomes
- Toxicity/adverse Events (AE) according to CTCAE v5.0 in patients treated with IP paclitaxel.
- HRQoL assessed using EORTC QLQ-C30 and EORTC OG-25 during treatment and follow-up.
- Progression-free survival (PFS), defined as time from randomisation to first documentation of progression according to RECIST1.1, progression of peritoneal carcinomatosis index (PCI), radiological progression of ascites, need for drainage of ascites or death, whichever occurs first.
- Radiological response of treatment on ascites present at baseline.
- Quantifying the amount of ascites drained from the randomisation date to date of censoring, death or end of study.
- Proportion of patients in each study arm, 1. Fulfilling the criteria for, 2. Undergoing, curative intent conversion surgery.
Investigators
Magnus Nilsson
Scientific
Karolinska University Hospital
Study Sites (8)
Loading locations...
Similar Trials
Recruiting
Not Applicable
Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian CancerNCT07261683Obstetrics & Gynecology Hospital of Fudan University20
Recruiting
Not Applicable
The Impact of Intraperitoneal Spray Combined With Intravenous Lidocaine on Postoperative Pain After MyomectomyNCT07268495General Hospital of Ningxia Medical University100
Recruiting
Phase 3
Establishment of standard treatment for pancreatic ductal adenocarcinoma with peritoneal metastasisInvasive ductal adenocarcinomaJPRN-jRCTs051180199Satoi Sohei180
Completed
Phase 2
Phase II study of intraperitoneal paclitaxel combined with S-1 plus cisplatin for advanced gastric cancer with peritoneal metastasisgastric cancer with peritoneal metastasisJPRN-UMIN000023000agoya University50
Completed
Phase 2
Phase II study of intraperitoneal paclitaxel combined with S-1 plus oxaliplatin as second-line chemotherapy for advanced gastric cancer with peritoneal metastasisgastric cancer with peritoneal metastasisJPRN-UMIN000012836The University of Tokyo50